FDA Inspection 1062725 — Tsao-Wei Liang
The FDA completed an inspection of Tsao-Wei Liang on Aug 10, 2018 in Philadelphia, PA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Aug 10, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Philadelphia, PA (United States)
Additional Details
Clinical Investigator (CI)